iPhone app draws FDA scrutiny; Synthes founder ponies up $125M for Harvard;

 @FierceMedDev: Roche wins FDA approval for novel diabetes diagnostic. More | Follow @FierceMedDev

 @MarkHFierce: Looks like Panasonic's bid to attract new investment for its healthcare arm is drawing major interest. Story | Follow @MarkHFierce

 @DamianFierce: Intuitive won its first da Vinci lawsuit, dodging $8.5M in damages. Article | Follow @DamianFierce

> Turkey is gearing up to produce its own medical equipment rather than importing the products. Story

> Regulators want to know why Biosense Technologies' iPhone app that lets diabetics check levels of blood, protein and other substances in their urine isn't FDA-cleared for use. Story

> Medical device manufacturer Advant Medical has committed a sizeable investment toward expanding its Galway, Ireland, plant. Story

> Johnson & Johnson ($JNJ) is suing Shasta Technologies, saying the company's logo infringes on its LifeScan unit's trademark. Article

> In a study, Biomet found that patients who received its Oxford Partial Knee implant were 1.8 times more likely than total-knee-replacement recipients to report that their knee felt normal and 2.7 times more likely to be happy with their ability to perform routine tasks. News

> Nephosity won the FDA's OK to start marking an imaging viewing mobile app for diagnostic use. Story   

> Synthes founder Hansjӧrg Wyss has given another $125 million to Harvard to advance the work of The Wyss Institute for Biologically Inspired Engineering, itself launched a few years back from Wyss's initial $125 million gift. Story

Biotech News

 @FierceBiotech: Check out this week's roundup of job changes in biopharma via @MichaelGFierce and @EmilyMFierce. Report | Follow @FierceBiotech

 @JohnCFierce: Aveo shares shellacked after Astellas drops EU game plan on kidney cancer. More | Follow @JohnCFierce

 @RyanMFierce: Merck marks another failure in elusive hunt for Parkinson's disease drugs. Article | Follow @RyanMFierce

> Amid deal frenzy, Elan rejects latest buyout bid from Royalty Pharma. Article

> Pfizer denies knowledge of acquired companies' failures in East German drug trials. Story

> Merck Serono CEO stakes out Boston biotech startups. More

Pharma News

 @FiercePharma: Novo Nordisk figures it could launch Victoza (liraglutide) as obesity treatment by end of 2014. Story | Follow @FiercePharma

 @EricPFierce: Yes, J&J has an impressive pipeline, but its extensions of existing drugs could add billions to the top line. Report | Follow @EricPFierce

> BRIC markets turning out to be tougher to mine than expected. More

> Former Carl Icahn proxy brawler Alex Denner joins fight against Vivus board. Story

> Novartis apologizes over Diovan study as probe shows employee involvement in trials. Article

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.